7/2/2015 | PP | Curis inks plans to conduct $30 million at-the-market sales agreement
|
3/2/2015 | PP | Curis greenshoe exercised in $69 million public sale of common stock
|
2/25/2015 | PP | Curis prices $60 million public offering of common stock at $2.75
|
2/24/2015 | PP | Curis announces it aims to conduct a public offering of common shares
|
11/28/2012 | PV | Curis subsidiary to borrow $30 million at 12.25% from Pharmakon fund for drug development
|
12/23/2010 | CVPF | Curis files $60 million shelf registration covering stock, preferreds
|
1/22/2010 | PP | New Issue: Curis orchestrates $16.25 million registered direct offering of units
|
7/29/2008 | CV | Curis files $50 million shelf registration
|
8/7/2007 | PP | Market Commentary: NPS Pharmaceuticals pockets $50 million; Azur wraps $48 million stock deal
|
8/6/2007 | PP | New Issue: Curis gears up to wrap $13 million placement of units
|
8/6/2007 | PP | Market Commentary: BioCryst secures $65.3 million from stock sale; Curis to close $13 million offering
|
11/2/2006 | BT | Curis plans to select first lead candidate from proprietary pipeline early next year
|
10/5/2006 | BT | Market Commentary: AnorMED up 7% as Genzyme boosts bid; GenVec gains 18%; Acorda rises; Light Sciences at bat
|
9/14/2006 | BT | Market Commentary: Threshold, Discovery Labs gain on widespread deal speculation; Curis better; Genzyme gains 3%
|
9/12/2006 | BT | Curis forms China-based subsidiary
|
9/1/2006 | BT | Market Commentary: Sanofi flu news pushes smaller biotechs lower; BioDelivery off 10%; Curis slips on R&D shift
|
9/1/2006 | BT | Curis, Genentech stop co-development of basal cell carcinoma drug
|
8/29/2006 | BT | Market Commentary: Teva lower; Endo, Penwest up; StemCells gains 7%; Nastech higher; Hemispherx rises 11%
|
7/12/2006 | BT | Market Commentary: Genzyme, Genentech 2Q results counteract; Curis retraces losses; Antigenics, CV, Cell Genesys up
|
7/11/2006 | BT | Curis, Genentech to halt phase 1 basal cell carcinoma trial
|
6/20/2006 | BT | Market Commentary: Discovery Labs bounces; Biomira looks for acquisitions; Curis hits new low; Human Genome higher
|
6/13/2006 | BT | Curis issued U.S. patent covering screening assays for antagonists, agonists of the Hedgehog pathway
|
6/8/2006 | BT | Curis shifts focus to later-stage drug development, appoints new chief scientific officer
|
5/16/2006 | BT | Curis: topical Hedgehog antagonist well tolerated in phase 1 trial of basal cell carcinoma
|
5/9/2006 | BT | Genentech to fund Curis researchers in Hedgehog carcinoma study
|
5/9/2006 | BT | Market Commentary: Hollis-Eden loses in advance of first-quarter report; Tercica dives 22% after close; Curis rises 17%
|
11/21/2005 | BT | Wyeth extends Curis funding to continue development of Hedgehog agonist for neurological disorders
|
10/25/2005 | BT | Curis: Data shows stimulating Hedgehog pathway effective against heart disease
|
10/13/2005 | BT | Curis receives second extension of funding from Genentech
|